Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 106CNS 13Gynecologic 11Sarcoma 8Gastrointestinal 8Tumor-Agnostic 7Thoracic 7Dermatologic 6Lymphoid 5Head & Neck 5Other solid neoplasm 4Endocrine 3Other hematologic neoplasm 2Genitourinary 2NET 1

Conditions

Multiple Endocrine Neoplasia Type 1 2Breast Neoplasms 2Neuroendocrine Tumors 1Neoplasms by Site 1Neoplasms 1Breast Diseases 1

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × ribociclib × Endocrine × Clear all
NCT03070301 2024-10-10

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
21 enrolled 8 charts
EndocrineNET

Neuroendocrine Tumors

NCT02422615 2023-11-30

MONALEESA-3

Novartis

Phase 3 Completed
726 enrolled 17 charts 1 FDA
BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

NCT03050398 2020-05-28

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

Novartis

Phase 3 Terminated
8 enrolled 4 charts
BreastEndocrine

Breast Neoplasms, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡